PLRX insider transaction filings
PLIANT THERAPEUTICS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-13. Screen PLRX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Borellini Flavia — Director | 1 | — | — | 1 |
| Iannone Robert — Director | 1 | — | — | 1 |
Recent Form 4 filings — PLIANT THERAPEUTICS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-13 | 4 | Borellini Flavia — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Iannone Robert — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Krognes Steve E. — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Cline Darren S — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Curnutte John T — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | MCCOURT Thomas A — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Huh Hoyoung — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | CROWELL GAYLE A — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Kuo Minnie — Chief Operating Officer | Disposition to issuer (D): 150,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 · Disposition to issuer (D): 40,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 · Disposition to issuer (D): 55,200 (derivative) @ $0 · Grant/award (A): 55,200 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Cummings Keith Lamont — Chief Financial Officer | Disposition to issuer (D): 76,047 (derivative) @ $0 · Grant/award (A): 76,047 (derivative) @ $0 · Disposition to issuer (D): 18,198 (derivative) @ $0 · Grant/award (A): 18,198 (derivative) @ $0 · Disposition to issuer (D): 74,250 (derivative) @ $0 · Grant/award (A): 74,250 (derivative) @ $0 · +8 more | EDGAR |
| 2026-04-17 | 4 | Coulie Bernard — President and CEO, Director | Disposition to issuer (D): 146,841 (derivative) @ $0 · Grant/award (A): 146,841 (derivative) @ $0 · Disposition to issuer (D): 327,262 (derivative) @ $0 · Grant/award (A): 327,262 (derivative) @ $0 · Disposition to issuer (D): 250,000 (derivative) @ $0 · Grant/award (A): 250,000 (derivative) @ $0 · +8 more | EDGAR |
| 2026-04-17 | 4 | Cheung Lily — Chief Human Resource Officer | Disposition to issuer (D): 123,000 (derivative) @ $0 · Grant/award (A): 123,000 (derivative) @ $0 · Disposition to issuer (D): 52,000 (derivative) @ $0 · Grant/award (A): 52,000 (derivative) @ $0 · Disposition to issuer (D): 51,750 (derivative) @ $0 · Grant/award (A): 51,750 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Cummings Keith Lamont — Chief Financial Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Kuo Minnie — Chief Operating Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Cheung Lily — Chief Human Resource Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Coulie Bernard — President and CEO, Director | Grant/award (A): 1,230,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Cummings Keith Lamont — Chief Financial Officer | Sale (S): 24,002 @ $1.28 | EDGAR |
| 2026-01-22 | 4 | Cheung Lily — Chief Human Resource Officer | Sale (S): 7,534 @ $1.28 | EDGAR |
| 2026-01-22 | 4 | Coulie Bernard — President and CEO, Director | Sale (S): 89,375 @ $1.28 | EDGAR |
| 2026-01-22 | 4 | Kuo Minnie — Chief Operating Officer | Sale (S): 6,917 @ $1.28 | EDGAR |
| 2025-06-09 | 4 | Knobil Katharine — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Krognes Steve E. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Cline Darren S — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Curnutte John T — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Bruhn Suzanne Louise — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | MCCOURT Thomas A — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Huh Hoyoung — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | CROWELL GAYLE A — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PYOTT DAVID E I — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Cheung Lily — Chief Human Resource Officer | Grant/award (A): 25,875 @ $0 · Grant/award (A): 51,750 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Ouimette Mike — General Counsel & Corp. Sec'y | Grant/award (A): 35,000 @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Hull Hans — Chief Business Officer | Grant/award (A): 40,150 @ $0 · Grant/award (A): 80,300 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Lefebvre Eric — Chief Medical Officer | Grant/award (A): 45,650 @ $0 · Grant/award (A): 91,300 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Cummings Keith Lamont — Chief Financial Officer | Grant/award (A): 56,650 @ $0 · Grant/award (A): 113,300 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Coulie Bernard — President and CEO, Director | Grant/award (A): 162,500 @ $0 · Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Coulie Bernard — President and CEO, Director | Sale (S): 52,419 @ $11.20 | EDGAR |
| 2025-01-22 | 4 | Cummings Keith Lamont — Chief Financial Officer | Sale (S): 20,148 @ $11.20 | EDGAR |
| 2025-01-22 | 4 | Cheung Lily — Chief Human Resource Officer | Sale (S): 3,740 @ $11.20 | EDGAR |
| 2025-01-22 | 4 | Ouimette Mike — General Counsel & Corp. Sec'y | Sale (S): 13,270 @ $11.20 · Sale (S): 10,230 @ $10.99 | EDGAR |
| 2025-01-22 | 4 | Hull Hans — Chief Business Officer | Sale (S): 15,936 @ $11.20 | EDGAR |
| 2025-01-22 | 4 | Lefebvre Eric — Chief Medical Officer | Sale (S): 18,478 @ $11.20 | EDGAR |
| 2024-07-12 | 4 | Cummings Keith Lamont — Chief Financial Officer | Sale (S): 10,911 @ $11.56 | EDGAR |
| 2024-07-12 | 4 | Coulie Bernard — President and CEO, Director | Sale (S): 38,710 @ $11.56 | EDGAR |
| 2024-07-12 | 4 | Ouimette Mike — General Counsel & Corp. Sec'y | Sale (S): 7,656 @ $11.56 | EDGAR |
| 2024-07-12 | 4 | Hull Hans — Chief Business Officer | Sale (S): 9,900 @ $11.56 | EDGAR |
| 2024-07-12 | 4 | Lefebvre Eric — Chief Medical Officer | Sale (S): 12,319 @ $11.56 | EDGAR |
| 2024-07-11 | 4 | Coulie Bernard — President and CEO, Director | Grant/award (A): 75,625 @ $0 | EDGAR |
| 2024-07-11 | 4 | Ouimette Mike — General Counsel & Corp. Sec'y | Grant/award (A): 14,954 @ $0 | EDGAR |
| 2024-07-11 | 4 | Hull Hans — Chief Business Officer | Grant/award (A): 19,337 @ $0 | EDGAR |
| 2024-07-11 | 4 | Lefebvre Eric — Chief Medical Officer | Grant/award (A): 24,063 @ $0 | EDGAR |
Recent 8-K events — PLIANT THERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-12-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PLRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →